Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
2.
J Pain ; 23(10): 1629-1645, 2022 10.
Article in English | MEDLINE | ID: mdl-35691467

ABSTRACT

Recent studies have shown that the incidence of chronic primary pain including temporomandibular disorders (TMD) and fibromyalgia syndrome (FMS) often exhibit comorbidities. We recently reported that central sensitization and descending facilitation system contributed to the development of somatic pain hypersensitivity induced by orofacial inflammation combined with stress. The purpose of this study was to explore whether TMD caused by unilateral anterior crossbite (UAC) can induce somatic pain hypersensitivity, and whether the cholecystokinin (CCK) receptor-mediated descending facilitation system promotes hypersensitivity through neuron-glia cell signaling cascade. UAC evoked thermal and mechanical pain hypersensitivity of the hind paws from day 5 to 70 that peaked at week 4 post UAC. The expression levels of CCK1 receptors, interleukin-18 (IL-18) and IL-18 receptors (IL-18R) were significantly up-regulated in the L4 to L5 spinal dorsal horn at 4 weeks post UAC. Intrathecal injection of CCK1 and IL-18 receptor antagonists blocked somatic pain hypersensitivity. IL-18 mainly co-localized with microglia, while IL-18R mainly co-localized with astrocytes and to a lesser extent with neurons. These findings indicate that the signaling transduction between neurons and glia at the spinal cord level contributes to the descending pain facilitation through CCK1 receptors during the development of the comorbidity of TMD and FMS. PERSPECTIVE: CCK1 receptor-dependent descending facilitation may mediate central mechanisms underlying the development of widespread somatic pain via a reciprocal neuron-glial signaling cascade, providing novel therapeutic targets for the clinical treatment of TMD and FMS comorbidities.


Subject(s)
Chronic Pain , Malocclusion , Nociceptive Pain , Receptor, Cholecystokinin B , Animals , Cholecystokinin/metabolism , Chronic Pain/metabolism , Hyperalgesia/metabolism , Interleukin-18/metabolism , Malocclusion/metabolism , Neuroglia/physiology , Neurons , Nociceptive Pain/metabolism , Rats , Rats, Sprague-Dawley , Receptor, Cholecystokinin B/metabolism , Receptors, Interleukin-18/metabolism , Signal Transduction/physiology , Spinal Cord , Spinal Cord Dorsal Horn/metabolism
3.
Eur J Pharmacol ; 913: 174619, 2021 Dec 15.
Article in English | MEDLINE | ID: mdl-34748768

ABSTRACT

In some chronic primary pain conditions such as temporomandibular disorder (TMD) and fibromyalgia syndrome (FMS), mild or chronic stress enhances pain. TMD and FMS often occur together, but the underlying mechanisms are unclear. The purpose of this study was to investigate the role of cholecystokinin (CCK) in the spinal cord in somatic hyperalgesia induced by orofacial inflammation combined with stress. Somatic hyperalgesia was detected by the thermal withdrawal latency and mechanical withdrawal threshold. The expression of CCK1 receptors, CCK2 receptors, ERK1/2 and p-ERK1/2 in the spinal cord was examined by Western blot. After the stimulation of orofacial inflammation combined with 3 day forced swim, the expression of CCK2 receptors and p-ERK1/2 protein in the L4-L5 spinal dorsal horn increased significantly, while the expression of CCK1 receptors and ERK1/2 protein remained unchanged. Intrathecal injection of the CCK2 receptor antagonist YM-022 or mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor PD98059 blocked somatic hyperalgesia induced by orofacial inflammation combined with stress. Intrathecal administration of the MEK inhibitor blocked somatic sensitization caused by the CCK receptor agonist CCK8. The CCK2 receptor antagonist YM-022 significantly reduced the expression of p-ERK1/2. These data indicate that upregulation of CCK2 receptors through the MAPK pathway contributes to somatic hyperalgesia in this comorbid pain model. Thus, CCK2 receptors and MAPK pathway may be potential targets for the treatment of TMD comorbid with FMS.


Subject(s)
Cholecystokinin/metabolism , Chronic Pain/immunology , Facial Pain/immunology , Hyperalgesia/immunology , Stress, Psychological/complications , Animals , Chronic Pain/pathology , Disease Models, Animal , Facial Pain/pathology , Female , Humans , Hyperalgesia/pathology , Inflammation/immunology , Inflammation/pathology , Rats , Rats, Sprague-Dawley , Receptor, Cholecystokinin B/metabolism , Spinal Cord Dorsal Horn/immunology , Spinal Cord Dorsal Horn/pathology , Stress, Psychological/immunology , Stress, Psychological/psychology
SELECTION OF CITATIONS
SEARCH DETAIL